help button home button Am J Pathol ASIP 2008 Summer Academy, Molecular Methcanisms of Human Disease: Injury, Inflammation, and Tissue Repair
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendriks, Y.
Right arrow Articles by Morreau, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendriks, Y.
Right arrow Articles by Morreau, H.
(American Journal of Pathology. 2003;162:469-477.)
© 2003 American Society for Investigative Pathology

Regular Articles

Conventional and Tissue Microarray Immunohistochemical Expression Analysis of Mismatch Repair in Hereditary Colorectal Tumors

Yvonne Hendriks*, Patrick Franken*, Jan Willem Dierssen{dagger}, Wiljo de Leeuw{dagger}, Juul Wijnen*, Enno Dreef{dagger}, Carli Tops*, Martijn Breuning*, Annette Bröcker-Vriends*, Hans Vasen{ddagger}, Riccardo Fodde* and Hans Morreau{dagger}

From the Center for Human and Clinical Genetics* and the Department of Pathology,{dagger} Leiden University Medical Center, Leiden; and the Netherlands Foundation for the Detection of Hereditary Tumors,{ddagger} Leiden, The Netherlands

Immunohistochemistry (IHC) of mismatch repair (MMR) proteins in colorectal tumors together with microsatellite analysis (MSI) can be helpful in identifying families eligible for mutation analysis. The aims were to determine sensitivity of IHC for MLH1, MSH2, and MSH6 and MSI analysis in tumors from known MMR gene mutation carriers; and to evaluate the use of tissue microarrays for IHC (IHC-TMA) of colon tumors in its ability to identify potential carriers of MMR gene mutations, and compare it with IHC on whole slides. IHC on whole slides was performed in colorectal tumors from 45 carriers of a germline mutation in one of the MMR genes. The TMA cohort consisted of 129 colon tumors from (suspected) hereditary nonpolyposis colorectal cancer (HNPCC) patients. Whole slide IHC analysis had a sensitivity of 89% in detecting MMR deficiency in carriers of a pathogenic MMR mutation. Sensitivity by MSI analysis was 93%. IHC can also be used to predict which gene is expected to harbor the mutation: for MLH1, MSH2, and MSH6, IHC on whole slides would have correctly predicted the mutation in 48%, 92%, and 75% of the cases, respectively. We propose a scheme for the diagnostic approach of families with (suspected) HNPCC. Comparison of the IHC results based on whole slides versus TMA, showed a concordance of 85%, 95%, and 75% for MLH, MSH2, and MSH6, respectively. This study therefore shows that IHC-TMA can be reliably used to simultaneously screen a large number of tumors from (suspected) HNPCC patients, at first in a research setting.




This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
J. Shia
Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome: Part I. The Utility of Immunohistochemistry
J. Mol. Diagn., July 1, 2008; 10(4): 293 - 300.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E R Nijhuis, H W Nijman, K A Oien, A Bell, K A ten Hoor, N Reesink-Peters, H M Boezen, H Hollema, and A G J van der Zee
Loss of MSH2 protein expression is a risk factor in early stage cervical cancer
J. Clin. Pathol., July 1, 2007; 60(7): 824 - 830.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin
Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials
Clin. Cancer Res., January 15, 2007; 13(2): 703s - 708s.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
Y. M.C. Hendriks, A. E. de Jong, H. Morreau, C. M.J. Tops, H. F. Vasen, J. Th. Wijnen, M. H. Breuning, and A. H.J.T. Brocker-Vriends
Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians
CA Cancer J Clin, July 1, 2006; 56(4): 213 - 225.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini
Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
Y Mueller-Koch, H Vogelsang, R Kopp, P Lohse, G Keller, D Aust, M Muders, M Gross, J Daum, U Schiemann, et al.
Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer
Gut, December 1, 2005; 54(12): 1733 - 1740.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. F. A. Vasen and C. R. Boland
Progress in Genetic Testing, Classification, and Identification of Lynch Syndrome
JAMA, April 27, 2005; 293(16): 2028 - 2030.
[Full Text] [PDF]

Home page
 JCOHome page
P. Th. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic, J. Kononen, A. Lugli, R. Simon, et al.
Prevalence of KIT Expression in Human Tumors
J. Clin. Oncol., November 15, 2004; 22(22): 4514 - 4522.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Perez-Ordonez, N N Huynh, K W Berean, and R C K Jordan
Expression of mismatch repair proteins, {beta} catenin, and E cadherin in intestinal-type sinonasal adenocarcinoma
J. Clin. Pathol., October 1, 2004; 57(10): 1080 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
E Mangold, C Pagenstecher, M Leister, M Mathiak, A Rutten, W Friedl, P Propping, T Ruzicka, and R Kruse
A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome
J. Med. Genet., July 1, 2004; 41(7): 567 - 572.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Struckmann, P. Schraml, R. Simon, K. Elmenhorst, M. Mirlacher, J. Kononen, and H. Moch
Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma
Cancer Res., March 1, 2004; 64(5): 1632 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
R A Oldenburg, W H de Vos tot Nederveen Cappel, M van Puijenbroek, A van den Ouweland, E Bakker, G Griffioen, P Devilee, C J Cornelisse, H Meijers-Heijboer, H F A Vasen, et al.
Extending the p16-Leiden tumour spectrum by respiratory tract tumours
J. Med. Genet., March 1, 2004; 41(3): e31 - 31.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. de Jong, M. van Puijenbroek, Y. Hendriks, C. Tops, J. Wijnen, M. G. E. M. Ausems, H. Meijers-Heijboer, A. Wagner, T. A. M. van Os, A. H. J. T. Brocker-Vriends, et al.
Microsatellite Instability, Immunohistochemistry, and Additional PMS2 Staining in Suspected Hereditary Nonpolyposis Colorectal Cancer
Clin. Cancer Res., February 1, 2004; 10(3): 972 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Simon, S. Panussis, R. Maurer, H. Spichtin, K. Glatz, C. Tapia, M. Mirlacher, A. Rufle, J. Torhorst, and G. Sauter
KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations
Clin. Cancer Res., January 1, 2004; 10(1): 178 - 183.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.